Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug combination increases life span of mice with ALS

01.04.2003


A new three-drug cocktail used to treat ALS, or Lou Gehrig’s Disease, may increase life span and decrease disease progression according to a study conducted at the Research Institute of the McGill University Health Centre (MUHC). The study, published in today’s issue of Annals of Neurology, is the first to look at this drug combination in a mouse model of ALS. This research was made possible by a partnership led by the Canadian Institutes of Health Research (CIHR), in conjunction with the ALS society of Canada and the Muscular Dystrophy Association of Canada (MDAC).



"Last year, we demonstrated that minocycline, a commonly prescribed antibiotic, on its own reduced disease progression, and delayed death in the ALS mice," says MUHC neuroscientist and senior author, Dr. Jean-Pierre Julien. "Findings from our current study show that a therapeutic approach based on a combination of minocycline with two other drugs is much more effective in delaying the onset of the disease and in increasing the longevity of the ALS mice."

"The results are very impressive," says Dr. Angela Genge, director of the ALS clinic at the Montreal Neurological Institute and Hospital. "The approach that Dr. Kriz and Dr Julien use is uniquely helpful in screening for potentially effective therapies in this cruel, currently incurable disease. Every gain gives us hope for the future."


"These research results give people who suffer from ALS hope, and show how well CIHR is working," said Dr. Rémi Quirion, Scientific Director of the Institute of Neurosciences, Mental Health and Addiction of the CIHR. "I have followed and admired Dr. Julien’s work for many years and it is important that the Government of Canada invest in this kind of research."

"These results provide hope to ALS patients and their families," says Centre Hospitalier de l’Universite de Montreal (CHUM) ALS clinician Dr. Monique D’Amour. "Because there is little effective treatment for ALS, new drug strategies are necessary. We will have to see if this will work in patients."

A steadily progressive and fatal neuromuscular disease, ALS erodes a person’s nervous system, eventually leading to paralysis and the inability to speak or swallow. People with ALS usually die within three to five years of diagnosis. Little is known about the cause of ALS and there is no cure. It is a disease of national importance, affecting between 1,500 and 2,000 people in Canada. Two to three Canadians a day die of ALS.

The discovery reported in this paper by Dr. Jasna Kriz, Ms. Geneviève Gowing and Dr. Julien is funded by a unique partnership between the ALS Society of Canada and the Muscular Dystrophy Association of Canada (MDAC). This partnership, in collaboration with the Canadian Institutes of Health Research (CIHR), has funded over $9 million of neuromuscular research since 2000.

"This is very exciting news for the ALS community," says Helene Vassos, interim National Executive Director for the ALS Society of Canada. "We are pleased that research, funded by our collaborative initiative with the MDAC and CIHR continues to result in important discoveries."

Dr. Julien, who is also a professor of Neurosciences at McGill University says that Dr. Kriz looked at the effect of combining three different drugs on the disease progression of ALS mice. The three drugs administered include minocyline- an antibiotic with anti-inflammatory properties, riluzole – the traditional ALS drug, and nimodipine – a drug that blocks calcium channels and normally used to treat brain hemorrhage and for prevention of migraine headache. Dr. Kriz compared the life span, muscle strength, nerve cell loss, and inflammatory response in ALS-mice who were fed a regular diet with those given food containing the three-drug cocktail. The mice fed the drug cocktail lived substantially longer, had a delayed onset of neuronal and muscle deterioration. "Our findings demonstrate the merit of a drug combination approach for treatment of a disease with complex degeneration pathways. The three drugs are currently available and we hope that our study will justify a trial on ALS patients," says Dr. Julien.

Christine Zeindler | EurekAlert!
Further information:
http://www.mcgill.ca/

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>